home / stock / tsha / tsha quote
Last: | $2.48 |
---|---|
Change Percent: | -0.38% |
Open: | $2.63 |
Close: | $2.48 |
High: | $2.65 |
Low: | $2.37 |
Volume: | 1,379,655 |
Last Trade Date Time: | 05/07/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.48 | $2.63 | $2.48 | $2.65 | $2.37 | 1,379,655 | 05-07-2024 |
$2.62 | $2.54 | $2.62 | $2.62 | $2.495 | 860,025 | 05-06-2024 |
$2.57 | $2.65 | $2.57 | $2.7499 | $2.54 | 1,053,341 | 05-03-2024 |
$2.58 | $2.49 | $2.58 | $2.64 | $2.41 | 1,491,558 | 05-02-2024 |
$2.42 | $2.44 | $2.42 | $2.505 | $2.35 | 1,403,562 | 05-01-2024 |
$2.43 | $2.54 | $2.43 | $2.54 | $2.4 | 1,172,564 | 04-30-2024 |
$2.45 | $2.41 | $2.45 | $2.595 | $2.39 | 1,944,961 | 04-29-2024 |
$2.39 | $2.35 | $2.39 | $2.45 | $2.295 | 890,189 | 04-26-2024 |
$2.3 | $2.35 | $2.3 | $2.375 | $2.165 | 1,560,849 | 04-25-2024 |
$2.35 | $2.53 | $2.35 | $2.54 | $2.32 | 793,938 | 04-24-2024 |
$2.53 | $2.56 | $2.53 | $2.61 | $2.48 | 1,458,646 | 04-23-2024 |
$2.46 | $2.28 | $2.46 | $2.47 | $2.19 | 1,459,716 | 04-22-2024 |
$2.27 | $2.4 | $2.27 | $2.43 | $2.145 | 1,790,537 | 04-19-2024 |
$2.41 | $2.45 | $2.41 | $2.49 | $2.32 | 1,969,323 | 04-18-2024 |
$2.45 | $2.58 | $2.45 | $2.59 | $2.435 | 1,398,013 | 04-17-2024 |
$2.575 | $2.69 | $2.575 | $2.7 | $2.5 | 1,475,522 | 04-16-2024 |
$2.66 | $2.95 | $2.66 | $3 | $2.63 | 2,029,832 | 04-15-2024 |
$2.94 | $3.22 | $2.94 | $3.28 | $2.93 | 1,683,837 | 04-12-2024 |
$3.22 | $3.23 | $3.22 | $3.355 | $3.04 | 3,255,716 | 04-11-2024 |
$3.14 | $2.85 | $3.14 | $3.4 | $2.85 | 4,738,013 | 04-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
Taysha Gene Therapies Inc. Company Name:
TSHA Stock Symbol:
NASDAQ Market:
DALLAS, May 07, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system (CNS), today announced that it...
RMAT designation follows FDA’s review of available safety and efficacy data from the first three patients dosed with the low dose of TSHA-102 across both REVEAL Phase 1/2 trials (adolescent/adult and pediatric) RMAT designation enables increased dialogue with the FDA to support t...
U.S. stock futures were mixed this morning, with the Dow futures gaining over 50 points on Friday. Shares of Applied Digital Corporation (NASDAQ: ...